Advertisement
News
Advertisement

External Trigeminal Nerve Stimulation (eTNS) For Refractory Status Epilepticus

Mon, 03/25/2013 - 3:17pm
Bio-Medicine.Org

LOS ANGELES, March 25, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch™ eTNS™ System for the adjunctive treatment of epilepsy and depression, at the 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures to be held in Salzburg, Austria from April 4-6, 2013. 

NeuroSigma's exhibit will feature the Monarch neuromodulation system. Conference attendees will be able to learn about the device and its safety and efficacy for patients whose epilepsy remains poorly controlled with drug therapy. NeuroSigma will be represented at the conference by Leon Ekchian, Ph.D., President and CEO, Christopher DeGiorgio , M.D., Vice President of Neurology at NeuroSigma and Professor of Neurology at the University of California Los Angeles (UCLA), and Colin Kealey , M.D., Manager of Business Development.

Case Study of the Use of eTNS for Status Epilepticus in the ICU

Status epilepticus is a life-threatening neurological emergency characterized by multiple or continuous seizures lasting longer than 5-10 minutes. Approximately 30-40% of patients with status epilepticus may develop refractory status epilepticus, where seizures continue longer than 1-hour after failing to respond to two or more antiepileptic drugs. Refractory status epilepticus is very lethal, with a mortality of 30-40%, and serious risk of neurological impairment. In the United States approximately 152,000 cases of status epilepticus occur annually, resulting in about 42,000 deaths and an inpatient cost of $3.8 to $7 billion per year.

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading